Want to see IN:SURAKSHA full AI Analyst Report?
Top Page
Suraksha Diagnostic Ltd.
(SURAKSHA)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹347.00
▲(9.26% Upside)
Action:Reiterated
Date:08/23/26
The score is driven primarily by solid but not flawless financial performance: improved growth/profitability versus FY23, but with FY26 margin volatility, rising leverage, and weak free-cash-flow conversion. Technicals are supportive with price above major moving averages and positive MACD, though momentum looks stretched (high RSI/Stoch). Valuation is the main headwind due to a high P/E and no dividend yield provided.
Positive Factors
Sustained Revenue Growth
Revenue growth has remained strong for three consecutive years after the FY23 contraction. This indicates improving demand and business scale, creating a durable foundation for operating leverage and continued expansion over the next several quarters.
Negative Factors
Margin Volatility
The sharp deterioration in gross margin and lower net margin point to possible pricing pressure, cost inflation, or adverse service mix. If persistent, this could limit operating leverage and make future earnings less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Revenue growth has remained strong for three consecutive years after the FY23 contraction. This indicates improving demand and business scale, creating a durable foundation for operating leverage and continued expansion over the next several quarters.
Read all positive factors
Suraksha Diagnostic Ltd. (SURAKSHA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹17.53B
Dividend Yield0.14%
Average Volume (3M)12.89K
Price to Earnings (P/E)47.7
Beta (1Y)1.01
Revenue Growth23.31%
EPS Growth7.56%
CountryIN
Employees1,600
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)6.18
Shares Outstanding52,080,757
10 Day Avg. Volume8,035
30 Day Avg. Volume12,892
Financial Highlights & Ratios
PEG Ratio32.20
Price to Book (P/B)4.85
Price to Sales (P/S)3.82
P/FCF Ratio70.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.65
Revenue Forecast (FY)₹3.68B
Suraksha Diagnostic Ltd. Business Overview & Revenue Model
Company Description
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics test...
How the Company Makes Money
null...
Suraksha Diagnostic Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
64
Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.10B | 2.52B | 2.19B | 1.90B | 2.23B |
| Gross Profit | 1.79B | 2.23B | 1.91B | 762.56M | 862.85M |
| EBITDA | 958.61M | 850.88M | 728.39M | 474.79M | 652.53M |
| Net Income | 321.87M | 318.24M | 236.26M | 65.16M | 208.24M |
Balance Sheet | |||||
| Total Assets | 4.48B | 3.34B | 3.00B | 2.81B | 2.76B |
| Cash, Cash Equivalents and Short-Term Investments | 263.48M | 226.36M | 515.96M | 522.79M | 412.89M |
| Total Debt | 1.30B | 888.86M | 904.76M | 968.74M | 997.95M |
| Total Liabilities | 2.05B | 1.23B | 1.21B | 1.26B | 1.30B |
| Stockholders Equity | 2.45B | 2.11B | 1.79B | 1.56B | 1.46B |
Cash Flow | |||||
| Free Cash Flow | 168.14M | 213.35M | 157.90M | 309.29M | 385.74M |
| Operating Cash Flow | 841.59M | 633.59M | 604.84M | 440.96M | 578.23M |
| Investing Cash Flow | -547.84M | -395.84M | -349.96M | -207.95M | -432.81M |
| Financing Cash Flow | -284.07M | -240.48M | -251.30M | -243.28M | -142.85M |
Suraksha Diagnostic Ltd. Technical Analysis
Positive
317.60
Price Trends
287.34
Positive
285.51
Positive
278.72
Positive
Market Momentum
14.78
Positive
57.88
Neutral
31.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SURAKSHA, the sentiment is Positive. The current price of 317.6 is below the 20-day moving average (MA) of 328.08, above the 50-day MA of 287.34, and above the 200-day MA of 278.72, indicating a neutral trend. The MACD of 14.78 indicates Positive momentum. The RSI at 57.88 is Neutral, neither overbought nor oversold. The STOCH value of 31.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SURAKSHA.
Suraksha Diagnostic Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | ₹28.10B | 35.55 | ― | 0.31% | 14.22% | 7.17% | |
78 Outperform | ₹90.34B | 32.52 | ― | 1.67% | 21.09% | 65.51% | |
74 Outperform | ₹322.18B | 59.08 | ― | 0.83% | 14.29% | 5.55% | |
63 Neutral | ₹17.53B | 47.65 | ― | 0.14% | 23.31% | 7.56% | |
61 Neutral | ₹18.18B | 18.79 | ― | 0.49% | 10.19% | 20.99% | |
59 Neutral | ₹124.83B | 61.20 | ― | 0.34% | 21.80% | 31.84% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:SURAKSHA
Suraksha Diagnostic Ltd.
327.85
15.50
4.96%
IN:KRSNAA
Krsnaa Diagnostics Limited
562.95
-275.40
-32.85%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,916.70
291.80
17.96%
IN:METROPOLIS
Metropolis Healthcare Ltd.
596.70
68.08
12.88%
IN:THYROCARE
Thyrocare Technologies Ltd
557.45
147.00
35.81%
IN:VIMTALABS
Vimta Labs Limited
635.40
-142.03
-18.27%
Suraksha Diagnostic Ltd. Corporate Events
Suraksha Diagnostic’s Company Secretary and Compliance Officer Resigns
Jun 9, 2026
Suraksha Diagnostic Limited has announced that Ms. Mamta Jain has resigned from her role as Company Secretary, Compliance Officer and Key Managerial Personnel, with her last working day set for July 15, 2026. The board has formally acknowledged he...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.